AIxCrypto Holdings, Inc. (AIXC) Stock Competitors & Peer Comparison

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ONC has a market cap of 28.7B. Regarding current trading prices, AIXC is priced at $1.30, while ONC trades at $264.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas ONC's P/E ratio is 60.53. In terms of profitability, AIXC's ROE is -0.94%, compared to ONC's ROE of +0.12%. Regarding short-term risk, AIXC is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ONC's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, AIXC is priced at $1.30, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas WBA's P/E ratio is -1.64. In terms of profitability, AIXC's ROE is -0.94%, compared to WBA's ROE of -0.42%. Regarding short-term risk, AIXC is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check WBA's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, AIXC is priced at $1.30, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas HROWL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, AIXC is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWL's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, AIXC is priced at $1.30, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas HROWM's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, AIXC is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, AVLN has a market cap of 1.3B. Regarding current trading prices, AIXC is priced at $1.30, while AVLN trades at $29.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas AVLN's P/E ratio is -12.69. In terms of profitability, AIXC's ROE is -0.94%, compared to AVLN's ROE of N/A. Regarding short-term risk, AIXC is less volatile compared to AVLN. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check AVLN's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CGEM has a market cap of 810M. Regarding current trading prices, AIXC is priced at $1.30, while CGEM trades at $11.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas CGEM's P/E ratio is -3.91. In terms of profitability, AIXC's ROE is -0.94%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, AIXC is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check CGEM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMD has a market cap of 233.1M. Regarding current trading prices, AIXC is priced at $1.30, while LFMD trades at $4.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas LFMD's P/E ratio is -10.95. In terms of profitability, AIXC's ROE is -0.94%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, AIXC is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFMD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HITI has a market cap of 204.8M. Regarding current trading prices, AIXC is priced at $1.30, while HITI trades at $2.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas HITI's P/E ratio is -5.55. In terms of profitability, AIXC's ROE is -0.94%, compared to HITI's ROE of -0.41%. Regarding short-term risk, AIXC is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HITI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMDP has a market cap of 161.9M. Regarding current trading prices, AIXC is priced at $1.30, while LFMDP trades at $23.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas LFMDP's P/E ratio is -10.53. In terms of profitability, AIXC's ROE is -0.94%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, AIXC is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMDP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, AIXC is priced at $1.30, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas LFLY's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.94%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, AIXC is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFLY's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, YI has a market cap of 37.5M. Regarding current trading prices, AIXC is priced at $1.30, while YI trades at $4.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas YI's P/E ratio is -0.56. In terms of profitability, AIXC's ROE is -0.94%, compared to YI's ROE of +0.14%. Regarding short-term risk, AIXC is less volatile compared to YI. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check YI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, AIXC is priced at $1.30, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas RAD's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.94%, compared to RAD's ROE of +2.76%. Regarding short-term risk, AIXC is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RAD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, PETS has a market cap of 36.5M. Regarding current trading prices, AIXC is priced at $1.30, while PETS trades at $1.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas PETS's P/E ratio is -0.62. In terms of profitability, AIXC's ROE is -0.94%, compared to PETS's ROE of -1.47%. Regarding short-term risk, AIXC is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check PETS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, SDEV has a market cap of 28.3M. Regarding current trading prices, AIXC is priced at $1.30, while SDEV trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas SDEV's P/E ratio is -0.18. In terms of profitability, AIXC's ROE is -0.94%, compared to SDEV's ROE of +17.15%. Regarding short-term risk, AIXC is more volatile compared to SDEV. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check SDEV's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, RKTO has a market cap of 27.1M. Regarding current trading prices, AIXC is priced at $1.30, while RKTO trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas RKTO's P/E ratio is -1.43. In terms of profitability, AIXC's ROE is -0.94%, compared to RKTO's ROE of -1.65%. Regarding short-term risk, AIXC is less volatile compared to RKTO. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RKTO's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, KYNB has a market cap of 27.1M. Regarding current trading prices, AIXC is priced at $1.30, while KYNB trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas KYNB's P/E ratio is -0.48. In terms of profitability, AIXC's ROE is -0.94%, compared to KYNB's ROE of -2.34%. Regarding short-term risk, AIXC is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check KYNB's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, RNTX has a market cap of 25.7M. Regarding current trading prices, AIXC is priced at $1.30, while RNTX trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas RNTX's P/E ratio is -0.48. In terms of profitability, AIXC's ROE is -0.94%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, AIXC is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RNTX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, NEUP has a market cap of 25.5M. Regarding current trading prices, AIXC is priced at $1.30, while NEUP trades at $4.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas NEUP's P/E ratio is -0.60. In terms of profitability, AIXC's ROE is -0.94%, compared to NEUP's ROE of -1.10%. Regarding short-term risk, AIXC is less volatile compared to NEUP. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check NEUP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, POM has a market cap of 14.4M. Regarding current trading prices, AIXC is priced at $1.30, while POM trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas POM's P/E ratio is -0.36. In terms of profitability, AIXC's ROE is -0.94%, compared to POM's ROE of +0.07%. Regarding short-term risk, AIXC is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POM's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, AIXC is priced at $1.30, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas MEDS's P/E ratio is -0.31. In terms of profitability, AIXC's ROE is -0.94%, compared to MEDS's ROE of -1.21%. Regarding short-term risk, AIXC is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MEDS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, AIXC is priced at $1.30, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas CJJD's P/E ratio is -0.46. In terms of profitability, AIXC's ROE is -0.94%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, AIXC is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CJJD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, AIXC is priced at $1.30, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas SSY's P/E ratio is -2.86. In terms of profitability, AIXC's ROE is -0.94%, compared to SSY's ROE of -0.15%. Regarding short-term risk, AIXC is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check SSY's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MSLE has a market cap of 7.8M. Regarding current trading prices, AIXC is priced at $1.30, while MSLE trades at $5.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas MSLE's P/E ratio is -3.37. In terms of profitability, AIXC's ROE is -0.94%, compared to MSLE's ROE of -0.67%. Regarding short-term risk, AIXC is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check MSLE's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, HKPD has a market cap of 3.7M. Regarding current trading prices, AIXC is priced at $1.30, while HKPD trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas HKPD's P/E ratio is -5.54. In terms of profitability, AIXC's ROE is -0.94%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, AIXC is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check HKPD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, AIXC is priced at $1.30, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas MDVL's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.94%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, AIXC is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MDVL's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, AIXC is priced at $1.30, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas ATNFW's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, AIXC is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check ATNFW's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, AIXC is priced at $1.30, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas BGMSP's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, AIXC is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMSP's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, AIXC is priced at $1.30, while BGMS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas BGMS's P/E ratio is 0.18. In terms of profitability, AIXC's ROE is -0.94%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, AIXC is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check BGMS's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, AIXC is priced at $1.30, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas AZNH's P/E ratio is 38.35. In terms of profitability, AIXC's ROE is -0.94%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check AZNH's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, AIXC is priced at $1.30, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.94%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, AIXC is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFLYW's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, AIXC is priced at $1.30, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas BIMI's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, AIXC is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BIMI's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas POZN's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to POZN's ROE of +0.61%. Regarding short-term risk, AIXC is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POZN's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas IPXL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, AIXC is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check IPXL's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas CPD's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to CPD's ROE of N/A. Regarding short-term risk, AIXC is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CPD's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas ESRX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, AIXC is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ESRX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas OREX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to OREX's ROE of -0.54%. Regarding short-term risk, AIXC is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check OREX's competition here

AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AIXC stands at 6.6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.30, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AIXC currently has a P/E ratio of -0.18, whereas SHPG's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, AIXC is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check SHPG's competition here